{
    "root": "2e6ef976-50b7-f96f-e063-6394a90a81b0",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Doxepin",
    "value": "20250218",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "FD&C BLUE NO. 1 ALUMINUM LAKE",
            "code": "J9EQA3S2JM"
        },
        {
            "name": "DOXEPIN HYDROCHLORIDE",
            "code": "3U9A0FE9N5"
        }
    ],
    "indications": "doxepin tablets indicated treatment insomnia characterized difficulty sleep maintenance . trials performed support efficacy 3 months duration .",
    "contraindications": "dose doxepin tablets individualized .",
    "warningsAndPrecautions": null,
    "adverseReactions": "hypersensitivity doxepin hydrochloride , inactive ingredients , dibenzoxepines . ( 4.1 ) co-administration monoamine oxidase inhibitors ( maois ) : administer patient taking maois used maois within past two weeks . ( 4.2 ) untreated narrow angle glaucoma severe urinary retention . ( 4.3 )",
    "indications_original": "Doxepin tablets are indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. The clinical trials performed in support of efficacy were up to 3 months in duration.",
    "contraindications_original": "The dose of doxepin tablets should be individualized.",
    "adverseReactions_original": "Hypersensitivity to doxepin hydrochloride, inactive ingredients, or other dibenzoxepines. ( 4.1 ) Co-administration with Monoamine Oxidase Inhibitors (MAOIs): Do not administer if patient is taking MAOIs or has used MAOIs within the past two weeks. ( 4.2 ) Untreated narrow angle glaucoma or severe urinary retention. ( 4.3 )"
}